Skip to main content
STADA Arzneimittel AG logo

STADA Arzneimittel AG — Investor Relations & Filings

Ticker · SAZ ISIN · DE0007251803 LEI · 529900FMTTLMH0P0DL10 HM Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2017-08-09 Declaration of Voting R…
Country DE Germany
Listing HM SAZ

About STADA Arzneimittel AG

https://www.stada.com/

STADA Arzneimittel AG is a pharmaceutical company that operates on a three-pillar strategy consisting of generics, consumer healthcare products, and specialty pharmaceuticals. The company is a leading manufacturer of affordable generic medicines, which have been a core part of its business since its founding. In the consumer healthcare segment, STADA markets a wide portfolio of over-the-counter (OTC) products and well-known brands. The specialty pharmaceuticals division focuses on developing and marketing value-added medicines, including an expanding portfolio of biosimilars for therapeutic areas such as oncology, immunology, and bone health.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German Securities Trading Act (WpHG). It reports changes in voting rights percentages (e.g., crossing thresholds from 6.74% to 8.40%) held by Morgan Stanley in STADA Arzneimittel AG. This directly corresponds to the definition of reporting changes in significant share ownership levels, which maps to the Major Shareholding Notification code (MRQ). Although the header mentions 'Voting Rights Announcements', the content is specifically about major holdings crossing thresholds, making MRQ a more precise fit than DVA (which is for voting results) or RNS (which is a fallback).
2017-08-09 English
STADA Arzneimittel AG: STADA shows good operational development in first six months of 2017
Earnings Release Classification · 100% confidence The document text provides detailed financial results for STADA Arzneimittel AG, covering the second quarter (Q2/2017) and the first six months (H1/2017) of the year. It includes key figures like Group sales, EBITDA, net income, segment performance (Generics and Branded Products), cash flow, and debt ratios. This structure—a comprehensive summary of financial performance for a specific interim period (six months)—is characteristic of an Interim or Quarterly Report. It is too detailed to be just an Earnings Release (ER) and is not the full annual filing (10-K). Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2017
2017-08-03 English
Datum:03.08.2017
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Zwischenbericht 1. Halbjahr und 2. Quartal 2017' (Interim Report for the 1st Half and 2nd Quarter 2017) for STADA Arzneimittel AG. It contains comprehensive financial tables (Konzern-Kennzahlen), management discussion and analysis (Konzernzwischenlagebericht), and detailed breakdowns of revenue and performance metrics. As it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2017
2017-08-03 German
Half-yearly financial report 2017
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report on the First Six Months and the Second Quarter of 2017' and contains comprehensive financial data, including consolidated income statements, balance sheets, cash flow statements, and management discussion and analysis. It is a full interim financial report, not an announcement or a summary, and therefore fits the definition of an Interim/Quarterly Report (IR). H1 2017
2017-08-03 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in shareholdings and voting rights percentages ('Notification of Major Holdings'). It references German securities law (WpHG) and details the resulting situation versus the previous notification, including voting rights attached to shares and instruments. This directly corresponds to the definition of a major shareholding notification, which is classified as 'MRQ' (Major Shareholding Notification) in the provided schema, as it details changes in significant ownership levels crossing thresholds.
2017-08-02 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German securities law (WpHG). It reports changes in voting rights percentages (crossing thresholds) held by Morgan Stanley in STADA Arzneimittel AG. This directly corresponds to the definition of a major shareholding notification, which is classified under the code MRQ (Major Shareholding Notification). Although the header mentions 'Voting Rights Announcements', the content is specifically about crossing major holding thresholds, making MRQ the most precise fit over DVA (Declaration of Voting Results) or RNS (General Regulatory Filing).
2017-08-02 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.